Analyst Price Targets — BCYC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 30, 2026 7:50 pm | Maury Raycroft | Jefferies | $12.00 | $4.72 | TheFly | Bicycle Therapeutics price target lowered to $12 from $13 at Jefferies |
| April 8, 2026 11:53 am | — | Morgan Stanley | $12.00 | $4.98 | TheFly | Bicycle Therapeutics price target lowered to $12 from $13 at Morgan Stanley |
| March 17, 2026 3:51 pm | Greg Renza | Truist Financial | $8.00 | $5.09 | StreetInsider | Bicycle Therapeutics (BCYC) PT Lowered to $8 at Truist Securities |
| March 17, 2026 12:29 pm | Maxwell Skor | Morgan Stanley | $13.00 | $5.13 | StreetInsider | Morgan Stanley on Bicycle Therapeutics (BCYC): program deprioritization 'disappointing,' but 'right call' |
| November 24, 2025 12:33 pm | — | Truist Financial | $10.00 | $6.32 | TheFly | Bicycle Therapeutics initiated with a Hold at Truist |
| October 31, 2025 9:59 am | Reni Benjamin | JMP Securities | $12.00 | $8.76 | TheFly | Bicycle Therapeutics price target raised to $12 from $10 at Citizens JMP |
| October 31, 2025 9:23 am | Leonid Timashev | RBC Capital | $11.00 | $8.76 | TheFly | RBC downgrades Bicycle Therapeutics on slow pipeline progress |
| August 11, 2025 1:08 pm | Leonid Timashev | RBC Capital | $27.00 | $7.59 | TheFly | Bicycle Therapeutics price target raised to $27 from $25 at RBC Capital |
| May 5, 2025 1:40 pm | Maxwell Skor | Morgan Stanley | $17.00 | $9.06 | TheFly | Bicycle Therapeutics price target raised to $17 from $15 at Morgan Stanley |
| December 18, 2024 11:28 am | Reni Benjamin | JMP Securities | $26.00 | $15.32 | TheFly | Bicycle Therapeutics price target lowered to $26 from $32 at JMP Securities |
Latest News for BCYC
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of initial data from the randomized Phase 2 trial (Duravelo-2) evaluating zelenectide pevedotin (zelenectide) in previously untreated patients with…
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the first quarter ended March 31, 2026, and provided recent corporate updates. “The data we reported in the first quarter continues to provide…
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced an oral presentation and multiple poster presentations across five abstracts at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, taking place May…
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updates from its EphA2 pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2026. “EphA2 is a potentially high value target that is widely…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BCYC.
U.S. House Trading
No House trades found for BCYC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.